Short Interest in IQVIA Holdings Inc. (NYSE:IQV) Expands By 11.0%

IQVIA Holdings Inc. (NYSE:IQV) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,120,000 shares, an increase of 11.0% from the December 15th total of 2,810,000 shares. Currently, 1.7% of the shares of the company are short sold. Based on an average daily volume of 1,530,000 shares, the short-interest ratio is currently 2.0 days.

IQVIA Trading Down 0.2 %

Shares of NYSE IQV traded down $0.41 during trading hours on Monday, hitting $197.25. 1,253,280 shares of the company traded hands, compared to its average volume of 1,057,891. The company’s 50 day moving average price is $200.09 and its 200 day moving average price is $221.39. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a market capitalization of $35.80 billion, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 2.09 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the third quarter valued at $28,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the second quarter worth about $29,000. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Finally, Assetmark Inc. boosted its position in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on IQV shares. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Leerink Partners reissued an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Morgan Stanley lowered their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Truist Financial reduced their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Finally, Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.